Pfizer revealed on Wednesday that it gave its first dose to a patient participating in its phase 2/3 clinical trial examining the efficacy of an orally administered drug that is designed to combat COVID-19. CEO Albert Bourla on Wednesday night wrote on Twitter that “success against COVID19 will likely require both vaccines [and] treatments” and said the pharmaceutical giant started a “Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults.” The drug, which has been dubbed PF-07321332, is designed for COVID-19 patients who haven’t been hospitalized but who have symptoms of the virus and are at low risk of seeing it progress to become a severe disease. The randomized, double-blind trial will enroll about 1,140 participants, who will get either PF-07321332 or a placebo orally every 12 hours for five days, according to a press release from Pfizer (pdf). “Protease inhibitors, like PF-07321332, are designed to block …